Better Therapeutics Inc (PK:BTTX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 548 Market St. #49404
SAN FRANCISCO CA 94101
Tel: N/A
Website: https://www.bettertx.com
IR: See website
<
Key People
Craig R. Jalbert
President, Chief Executive Officer, Treasurer, Company Secretary, Director
   
Business Overview
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
Financial Overview
For the nine months ended 30 September 2023, Better Therapeutics Inc revenues was not reported. Net loss decreased 26% to $22.8M. Lower net loss reflects Research and development - Balancing val decrease of 46% to $7M (expense), General and administrative - Balancing v decrease of 24% to $7.9M (expense), Stock-based Compensation in SG decrease of 19% to $721K (expense).
Employees: 54 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $7.71M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$26.50M as of Sep 30, 2023
Net annual income (TTM): -$31.57M as of Sep 30, 2023
Free cash flow (TTM): -$27.40M as of Sep 30, 2023
Net Debt Last Fiscal Year: $7.71M as of Sep 30, 2023
Shares outstanding: 49,861,726 as of Dec 1, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.